EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis - PubMed (original) (raw)

. 2021 Apr;76(4):988-1009.

doi: 10.1111/all.14690. Epub 2020 Dec 27.

Cezmi A Akdis 2 3, Mubeccel Akdis 2, Knut Brockow 4, Tomas Chivato 5, Stefano Del Giacco 6, Thomas Eiwegger 7 8 9, Kilian Eyerich 10, Ana Giménez-Arnau 11, Jan Gutermuth 12, Emma Guttman-Yassky 13, Marcus Maurer 14, Graham Ogg 15, Peck Y Ong 16, Liam O'Mahony 17, Jürgen Schwarze 18, Amena Warner 19, Thomas Werfel 20, Oscar Palomares 21, Marek Jutel 22 [ 23](#full-view-affiliation-23 "ALL-MED" Medical Research Institute, Wroclaw, Poland.")

Affiliations

EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis

Ioana Agache et al. Allergy. 2021 Apr.

Abstract

Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.

Keywords: GRADE; atopic dermatitis; dupilumab; guideline.

© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

PubMed Disclaimer

References

REFERENCES

    1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360.
    1. Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836-845.
    1. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018;73(6):1284-1293.
    1. Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis. A systematic review. Acta DermVenereol. 2020;100(12):adv00160.
    1. Stefanovic N, Flohr C, Irvine AD. The exposome in atopic dermatitis. Allergy. 2020;75(1):63-74.

MeSH terms

Substances

Grants and funding

LinkOut - more resources